Champignon Brands, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Investors with losses are encouraged to contact the firm before June 9, 2021; click here to submit trade information

The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Champignon Brands, Inc. (OTC: SHRMF) investors that acquired shares between March 27, 2020 and February 17, 2021. Investors have until June 9, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.

It is alleged in this complaint that Champignon made misleading and false statements to the market. Sufficient internal controls over financials were not maintained by Champignon. Champignon issued financial statements that were false and could not be relied upon, requiring restatement. Champignon engaged in acquisitions with undisclosed third parties, and as a result, the British Columbia Securities Commission would suspend Champignon from trading. Champignon's public statements were materially misleading and false throughout the class period, as a result. Investors suffered damages when the market learned the truth about Champignon.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 9, 2021 .

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...
Emyria Limited

Emyria Launches Global Services Platform Targeting International Drug Sponsors

Emyria’s established, world-first, unique national clinical delivery network to drive a new services-led revenue stream focused on global drug sponsors.

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce the launch of its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access Emyria’s established clinical delivery... Keep Reading...
Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with an emphasis on safe, evidence-based psychedelic-assisted therapies, is providing an update regarding its listing status on the... Keep Reading...
Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update

Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Corporate UpdateOver the past year,... Keep Reading...
Numinus Wellness Advises of a Change of Auditor

Numinus Wellness Advises of a Change of Auditor

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is advising of a change of its auditor. The Company's previous... Keep Reading...
Lobe Sciences Reports First Quarter 2026 Results and Highlights

Lobe Sciences Reports First Quarter 2026 Results and Highlights

VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / lobe sciences ltd. (CSE:LOBE,OTC:LOBEF)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited financial results for the first... Keep Reading...

Interactive Chart

Latest Press Releases

Related News